Abstract
Fundamental and clinical studies on PC-904, a new semisynthetic penicillin developed by Sumitomo Chemical Company Limited, were performed in 46 institutions in Japan and the results were presented at the 25th Congress of Chemotherapy (the annual meeting of Japan Society of Chemotherapy), New Drug Symposium, Gifu, 1977. The results are summarized as follows.
1) In vitro activity of PC-904 against Pseudomonas and other gram-negative bacteria was more potent than the other broad-spectrum penicillins.
2) When 2g of PC-904 were administered by drip infusion, the peak serum level was more than 100μg/ml and its urinary recovery within 6 hours was more than 30%. It was characteristic that 50-60% of administered dose was excreted in bile.
3) Clinical effects of PC-904 against various infections were analyzed by the results of 613 cases out of total 650 cases treated with PC-904. The effective rate in 335 cases of the field of internal medicine was 63. 6% and the effective rate in 275 cases in the field of surgery, urology, obstetrics and gynecology, otorhinolaryngology and ophthalmology was 72.4%, and the effective rate in total of 613 cases was 67.5%.
4) No severe side effects were observed while incidence of allergic reactions was comparatively high. Abnormalities in laboratory findings were observed in some cases, but they turned to normal immediately after discontinuing the drug.
